Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
patients quality of life
1
The outcome of a post-hoc analysis of the phase 2b study published in the Journal of the European Academy of Dermatology and Venerology provides new possibilities for patients struggling with uncontrolled atopic dermatitis
Clinical trial subjects treated with nemolizumab demonstrated significant itch relief as early as 48 hours after treatment
that persisted throughout the duration of the study (up to week 16)
2
Subjects treated with nemolizumab reported significant sleep improvements as early as 72 hours after the first injection which were sustained, and improved further throughout the duration of the trial (up to week 16)
Galderma Continues Global Growth Ambition With Sculptra (injectable poly-L-lactic Acid) Re-launch in Europe
Updated protocol allows for faster and more convenient administration of
Sculptra
with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra (injectable poly-L-lactic acid) a collagen stimulator with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.
Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
Thursday, March 4, 2021 1:52PM IST (8:22AM GMT)
Updated protocol allows for faster and more convenient administration of
Sculptra® with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra®
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra
® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.